bioMérieux S.A. (OTCMKTS:BMXMF - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $142.41 and last traded at $142.41, with a volume of 34 shares. The stock had previously closed at $136.00.
Analyst Upgrades and Downgrades
Separately, Royal Bank of Canada cut shares of bioMérieux from a "moderate buy" rating to a "hold" rating in a report on Wednesday, May 7th.
Read Our Latest Research Report on BMXMF
bioMérieux Trading Down 0.7%
The stock's 50 day moving average price is $130.62 and its two-hundred day moving average price is $120.24. The company has a quick ratio of 1.20, a current ratio of 2.21 and a debt-to-equity ratio of 0.10.
bioMérieux Company Profile
(
Get Free Report)
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.
Featured Articles
Before you consider bioMerieux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bioMerieux wasn't on the list.
While bioMerieux currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
